Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director | February 27, 2026 | March 02, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director · President and CEO | August 24, 2026 | August 24, 2026 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | September 14, 2026 | September 17, 2026 |
| Zosano Pharma CorpZSAN · Entity 12518 | Director | January 02, 2019 | July 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atrium Therapeutics, Inc.
Report date February 27, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2036-02-27 | Direct | 20,000 |
Reported balance
After 2026-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 20,000 · Balance 20,000 F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Kura Oncology, Inc.
Report date August 24, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby One Fish Two Fish Revocable Trust | 479,194 |
Reported balance
After 2026-08-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-24 · Purchase · Acquired 100,000 · Balance 479,194 F1: This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Indirectby Lorax Charitable Remainder Unitrust | 300,000 |
Reported balance
Holding disclosure · report date 2026-08-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,000 |
| Common StockSEC Table I · non-derivative | Direct | 435,456 |
Reported balance
Holding disclosure · report date 2026-08-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 435,456 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
PUMA BIOTECHNOLOGY, INC.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,750 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Sale · Disposed 5,000 · Balance 54,750 F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026 |
| Common StockSEC Table I · non-derivative | IndirectBy Child #1 | 400 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 400 |
| Common StockSEC Table I · non-derivative | IndirectBy Child #2 | 150 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 150 |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026
Zosano Pharma Corp
Report date January 02, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2029-01-02 | Direct | 1,500 |
Reported balance
After 2019-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 1,500 · Balance 1,500 F1: The shares underlying the option shall vest on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest on the first anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 65,091 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 13,711 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2023 Filed Dec 14, 2023 11:50 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | OtherCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-23-000101 · wk-form4_1702554646.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 263,711 F1 · kind: Represents a transfer for no value from the Reporting Person to a trust established for the benefit of the Reporting Person's family. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058040 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 279,194 Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058040 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001599901-23-000050 · wk-form4_1687291647.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:14 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-017612 · rdgdoc.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,350 F3 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:14 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,000 | $3.45 | $93,268.80 |
DisclosureSEC source: 0001437749-23-017612 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 27,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 8 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,559 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. As a consequence of this transfer, the reporting person will no longer have beneficial ownership of the shares. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 7 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by Lorax Charitable Remainder Unitrust Disclosed balance after: 300,000 F1 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 280,194 F1 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 580,194 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. As a consequence of this transfer, the reporting person will no longer have beneficial ownership of the shares. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 212,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 880,194 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. As a consequence of this transfer, the reporting person will no longer have beneficial ownership of the shares. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 41,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 1,092,694 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. As a consequence of this transfer, the reporting person will no longer have beneficial ownership of the shares. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 8,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 1,134,012 F1 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 8,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033892 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 0 F1 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another trust established by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 560,000 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · derivative · entry 8 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2033-02-15 F4 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| October 06, 2022 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 1,084,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · nonDerivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 1,125,618 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another grantor trust established by the reporting person. Read SEC document |
| October 06, 2022 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 1,084,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · nonDerivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 8,394 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another grantor trust established by the reporting person. Read SEC document |
| August 19, 2022 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 11,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · nonDerivative · entry 7 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,525 F1 · kind: Shares were transferred to the reporting person's former spouse pursuant to a divorce settlement. The securities owned by the former spouse are not beneficially owned by the reporting person. F3 · balance_after: Includes 1,109 shares acquired on November 17, 2021 and 1,450 shares acquired on May 17, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| August 19, 2022 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 41,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 41,318 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another grantor trust established by the reporting person. Read SEC document |
| August 19, 2022 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 41,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 1,092,694 F2 · kind: This transaction represents a transfer of shares of common stock without consideration from a grantor trust established by the reporting person to another grantor trust established by the reporting person. Read SEC document |
| August 19, 2022 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 17,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 1,134,012 F1 · kind: Shares were transferred to the reporting person's former spouse pursuant to a divorce settlement. The securities owned by the former spouse are not beneficially owned by the reporting person. Read SEC document |
| July 14, 2022 Filed Feb 21, 2023 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 468,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011276 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 1,151,720 F1 · kind: Shares were transferred to the reporting person's former spouse pursuant to a divorce settlement. The securities owned by the former spouse are not beneficially owned by the reporting person. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 23:12 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,858 | $2.58 | $71,971.14 |
DisclosureSEC source: 0001437749-22-015529 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,350 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.544 to $2.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 18, 2022 00:52 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001209191-22-038222 · doc4.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-015210 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,208 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 495,000 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005360 · doc4.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,000 Underlying: Common Stock · 495,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:11 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001209191-21-041153 · doc4.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 01:11 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 27,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041803 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,208 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 23:30 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 25,748 | $11.36 | $292,432.91 |
DisclosureSEC source: 0001209191-21-040041 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.24 to $11.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 22:16 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 366,500 | $0.00 Strike: $32.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005903 · doc4.xml · derivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,500 Underlying: Common Stock · 366,500 shares Expires 2031-01-25 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| December 23, 2020 Filed Jan 28, 2021 22:16 UTC | Kura Oncology, Inc. KURA · Entity 4871 | OtherCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005903 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 1,620,017 F1 · kind: This line item reflects a transfer of 175,000 shares of common stock of Kura Oncology, Inc. (the "Shares") held by a grantor trust established by the reporting person to an incomplete non-grantor trust for estate planning purposes. As a consequence of this transfer, the reporting person will no longer have beneficial ownership of the Shares. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:49 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | OtherCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065194 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust 2 Disclosed balance after: 100,000 F1 · kind: Represents a transfer for no value from the Reporting Person to a trust established for the benefit of the Reporting Person's family. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:49 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | OtherCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065194 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,618 F1 · kind: Represents a transfer for no value from the Reporting Person to a trust established for the benefit of the Reporting Person's family. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 11,855 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-061111 · doc4.xml · derivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,210 Underlying: Common Stock · 11,855 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on 1/23/2017. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 11,855 | $6.15 | $72,908.25 |
DisclosureSEC source: 0001209191-20-061111 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 50,370 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · derivative · entry 10 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,065 Underlying: Common Stock · 50,370 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 23, 2017. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 50,370 | $34.00 | $1,712,580.00 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · nonDerivative · entry 7 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 50,370 | $6.15 | $309,775.50 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · nonDerivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 106,736 | $34.00 | $3,629,024.00 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 0 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 4,586 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · derivative · entry 9 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,435 Underlying: Common Stock · 4,586 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 23, 2017. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,586 | $34.00 | $155,924.00 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · nonDerivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 4,586 | $6.15 | $28,203.90 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 99,900 | $32.00 | $3,196,800.00 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 106,736 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:55 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 100 | $32.00 | $3,200.00 |
DisclosureSEC source: 0001209191-20-054328 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 206,636 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 98,490 | $28.82 | $2,838,875.76 |
DisclosureSEC source: 0001209191-20-050590 · doc4.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 206,736 F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $28.00 to $29.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 23:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 17,926 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-050590 · doc4.xml · derivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,021 Underlying: Common Stock · 17,926 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F4 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 23, 2017. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 23:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 485 | $28.00 | $13,580.00 |
DisclosureSEC source: 0001209191-20-050590 · doc4.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 305,226 F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 23:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 17,926 | $28.00 | $501,928.00 |
DisclosureSEC source: 0001209191-20-050590 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 23:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 17,926 | $6.15 | $110,244.90 |
DisclosureSEC source: 0001209191-20-050590 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| September 10, 2020 Filed Sep 10, 2020 22:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 37,030 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-050028 · doc4.xml · derivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,947 Underlying: Common Stock · 37,030 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 23, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.